

Claude F. Meares, et al.
Application No.: 09/671,953
Page 2

PATENT

IN THE SPECIFICATION:

On page 1, beginning at line 17, please insert the following replacement paragraph.

F1
Over a million new cases of cancer will be diagnosed this year in the United States. While surgery can often provide definitive treatment of cancer in its early stages, the eradication of metastases is crucial to the cure of more advanced disease. Chemotherapeutic drugs are used in combinations for this purpose, with considerable success. Nonetheless, over half a million Americans will die from cancer this year. Progressions and relapses following surgery and chemotherapy/radiation are not uncommon, and in most cases the second line of treatment is of limited use. Despite the expenditure of large amounts of public and private resources over many years, better treatments for cancer are sorely needed.

On page 74, beginning at line 5, please insert the following replacement paragraph.

F2
The three mutant Fabs, the native chimeric (ATCC Deposit No. PTA-4696, made September 19, 2002, at the ATCC, 10801 University Blvd. Manassas, VA 20110-2209), the S95C mutant and the N96C mutant, were expressed by cotransfection in S2 cells of the plasmid bearing the heavy chain with a plasmid carrying one of the three differing light chains. Culture medium of each of the respective Fab expressing cell lines was analyzed by reducing SDS-PAGE followed by Western blotting with immunostaining via the C-terminal epitope tag present on the heavy chain (FIG. 16). This staining process shows a band at 26kD as expected. ELISA analysis of the culture medium samples with indium benzyl-EDTA-HSA conjugate coated plates demonstrated that all chimeric Fabs bound the hapten in a concentration dependent manner (FIG. 17).

IN THE CLAIMS:

Please amend claims 1, 14, 22, 25, 42 and 43 as follows: